A gelatin-albumin (Gel-Alb) hybrid nanoparticle was generated and evaluated for its drug efficacy as an anti-cancer drug delivery system in a panel of subtype-specific breast cancer cell lines. The gene discussed is ALB; the disease is breast carcinoma.